97 related articles for article (PubMed ID: 23647062)
1. Bortezomib down-modulates the survival factor interferon regulatory factor 4 in Hodgkin lymphoma cell lines and decreases the protective activity of Hodgkin lymphoma-associated fibroblasts.
Celegato M; Borghese C; Casagrande N; Carbone A; Colombatti A; Aldinucci D
Leuk Lymphoma; 2014 Jan; 55(1):149-59. PubMed ID: 23647062
[TBL] [Abstract][Full Text] [Related]
2. NF-kappaB-independent down-regulation of XIAP by bortezomib sensitizes HL B cells against cytotoxic drugs.
Kashkar H; Deggerich A; Seeger JM; Yazdanpanah B; Wiegmann K; Haubert D; Pongratz C; Krönke M
Blood; 2007 May; 109(9):3982-8. PubMed ID: 17185461
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies.
Zhao X; Qiu W; Kung J; Zhao X; Peng X; Yegappan M; Yen-Lieberman B; Hsi ED
Leuk Res; 2008 Feb; 32(2):275-85. PubMed ID: 17659339
[TBL] [Abstract][Full Text] [Related]
4. IRF4 silencing inhibits Hodgkin lymphoma cell proliferation, survival and CCL5 secretion.
Aldinucci D; Celegato M; Borghese C; Colombatti A; Carbone A
Br J Haematol; 2011 Jan; 152(2):182-90. PubMed ID: 21114485
[TBL] [Abstract][Full Text] [Related]
5. The NF-κB inhibitor DHMEQ decreases survival factors, overcomes the protective activity of microenvironment and synergizes with chemotherapy agents in classical Hodgkin lymphoma.
Celegato M; Borghese C; Umezawa K; Casagrande N; Colombatti A; Carbone A; Aldinucci D
Cancer Lett; 2014 Jul; 349(1):26-34. PubMed ID: 24704296
[TBL] [Abstract][Full Text] [Related]
6. IRF4 is modulated by CD40L and by apoptotic and anti-proliferative signals in Hodgkin lymphoma.
Aldinucci D; Rapana' B; Olivo K; Lorenzon D; Gloghini A; Colombatti A; Carbone A
Br J Haematol; 2010 Jan; 148(1):115-8. PubMed ID: 19821826
[TBL] [Abstract][Full Text] [Related]
7. PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor.
Zhao WL; Liu YY; Zhang QL; Wang L; Leboeuf C; Zhang YW; Ma J; Garcia JF; Song YP; Li JM; Shen ZX; Chen Z; Janin A; Chen SJ
Blood; 2008 Apr; 111(7):3867-71. PubMed ID: 18235046
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib inhibits proteasomal degradation of IκBα and induces mitochondrial dependent apoptosis in activated B-cell diffuse large B-cell lymphoma.
Bu R; Hussain AR; Al-Obaisi KA; Ahmed M; Uddin S; Al-Kuraya KS
Leuk Lymphoma; 2014 Feb; 55(2):415-24. PubMed ID: 23697845
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib induces apoptosis in T lymphoma cells and natural killer lymphoma cells independent of Epstein-Barr virus infection.
Iwata S; Yano S; Ito Y; Ushijima Y; Gotoh K; Kawada J; Fujiwara S; Sugimoto K; Isobe Y; Nishiyama Y; Kimura H
Int J Cancer; 2011 Nov; 129(9):2263-73. PubMed ID: 21170988
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.
Chen KF; Yeh PY; Yeh KH; Lu YS; Huang SY; Cheng AL
Cancer Res; 2008 Aug; 68(16):6698-707. PubMed ID: 18701494
[TBL] [Abstract][Full Text] [Related]
11. Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions.
Aldinucci D; Lorenzon D; Cattaruzza L; Pinto A; Gloghini A; Carbone A; Colombatti A
Int J Cancer; 2008 Feb; 122(4):769-76. PubMed ID: 17935139
[TBL] [Abstract][Full Text] [Related]
12. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.
Strauss SJ; Higginbottom K; Jüliger S; Maharaj L; Allen P; Schenkein D; Lister TA; Joel SP
Cancer Res; 2007 Mar; 67(6):2783-90. PubMed ID: 17363600
[TBL] [Abstract][Full Text] [Related]
13. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
[TBL] [Abstract][Full Text] [Related]
14. [Proliferation-inhibiting and multidrug-resistant reversing effect of bortezomib on human HL-60 cells].
Shang J; Chen ZZ; Wu WB; Wei TN; Chen WM
Zhonghua Xue Ye Xue Za Zhi; 2012 Nov; 33(11):911-6. PubMed ID: 23363746
[TBL] [Abstract][Full Text] [Related]
15. Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206.
Blum KA; Johnson JL; Niedzwiecki D; Canellos GP; Cheson BD; Bartlett NL
Leuk Lymphoma; 2007 Jul; 48(7):1313-9. PubMed ID: 17613759
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib inhibits expression of TGF-β1, IL-10, and CXCR4, resulting in decreased survival and migration of cutaneous T cell lymphoma cells.
Chang TP; Poltoratsky V; Vancurova I
J Immunol; 2015 Mar; 194(6):2942-53. PubMed ID: 25681335
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma.
Noborio-Hatano K; Kikuchi J; Takatoku M; Shimizu R; Wada T; Ueda M; Nobuyoshi M; Oh I; Sato K; Suzuki T; Ozaki K; Mori M; Nagai T; Muroi K; Kano Y; Furukawa Y; Ozawa K
Oncogene; 2009 Jan; 28(2):231-42. PubMed ID: 18850009
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells.
Tsapakidis K; Vlachostergios PJ; Voutsadakis IA; Befani CD; Patrikidou A; Hatzidaki E; Daliani DD; Moutzouris G; Liakos P; Papandreou CN
Int J Urol; 2012 Jun; 19(6):565-74. PubMed ID: 22324515
[TBL] [Abstract][Full Text] [Related]
19. Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-kappaB pathways.
Rizzatti EG; Mora-Jensen H; Weniger MA; Gibellini F; Lee E; Daibata M; Lai R; Wiestner A
Leuk Lymphoma; 2008 Apr; 49(4):798-808. PubMed ID: 18398749
[TBL] [Abstract][Full Text] [Related]
20. Hodgkin lymphoma: Pathology and biology.
Mathas S; Hartmann S; Küppers R
Semin Hematol; 2016 Jul; 53(3):139-47. PubMed ID: 27496304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
